Johannesson M, Borgquist L, Jönsson B
Department of Health and Society, Linköping University, Sweden.
Scand J Prim Health Care. 1991 Sep;9(3):155-60. doi: 10.3109/02813439109018511.
The treatment costs of hypertension in Sweden were calculated both at the individual and at the national level after an empirical investigation in primary health care. The average drug cost per patient and year was calculated as c. SEK 1220, the annual consultation cost as c. SEK 620, and the annual travel and time cost as c. SEK 230. About 500,000 people are treated pharmacologically for hypertension in Sweden, and about 25,000 non-pharmacologically. The total annual treatment cost for these patients was calculated as c. SEK 1100 million. The drug cost accounts for c. SEK 650 million, the consultation cost for c. SEK 330 million, and the travel and time cost for c. SEK 120 million. The drug reimbursement scheme pays almost half these costs, while the county councils and the patients pay approximately a quarter each.
在对初级卫生保健进行实证调查后，计算了瑞典高血压的个体治疗成本和国家层面的治疗成本。每位患者每年的平均药物成本约为1220瑞典克朗，每年的诊疗成本约为620瑞典克朗，每年的交通和时间成本约为230瑞典克朗。瑞典约有50万人接受高血压药物治疗，约2.5万人接受非药物治疗。这些患者的年度总治疗成本约为11亿瑞典克朗。药物成本约为6.5亿瑞典克朗，诊疗成本约为3.3亿瑞典克朗，交通和时间成本约为1.2亿瑞典克朗。药物报销计划支付了这些成本的近一半，而郡议会和患者各支付约四分之一。
